Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
79 hedge funds and large institutions have $42M invested in Bellicum Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 24 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
16% less funds holding
Funds holding: 94 → 79 (-15)
23% less call options, than puts
Call options by funds: $31K | Put options by funds: $40K
51% less capital invested
Capital invested by funds: $85.1M → $42M (-$43.1M)
54% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$2.83M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$2.83M |
| 3 |
Renaissance Technologies
New York
|
+$1.57M |
| 4 |
Goldman Sachs
New York
|
+$1.4M |
| 5 |
Jane Street
New York
|
+$654K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.35M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.55M |
| 3 |
JP Morgan Chase
New York
|
-$2.19M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.81M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$957K |
BLCM Hedge Fund Activity: Q2 2019 in Review
79 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2019, worth a combined $42M — down 51% from $85.1M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BLCM and 11 opened new positions — a net loss of 13 holders — while 21 trimmed existing stakes and 26 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $2.83M. The largest seller was BlackRock, cutting an estimated $4.35M.
- 79 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2019, down from 94 in Q1 2019.
- Funds reported $42M of Bellicum Pharmaceuticals, Inc. stock for Q2 2019, down 51% quarter-over-quarter.
- 11 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2019 and 24 closed out, a net change of -13 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2019 was Nikko Asset Management Americas, an estimated $2.83M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2019 was BlackRock, an estimated $4.35M sold.
Based on aggregated 13F filings for Q2 2019.